Novo VP Weighs In on Approval of Lilly’s Obesity Pill

This is a live story built from multiple sources. It may evolve quickly.

Coverage meter • 1 min window

Back to home Open top source

B bloomberg.com

What’s included

Top recent items from this story.

1 items • 1 unique links

Bloomberg Markets 4 days ago • bloomberg.com

Novo VP Weighs In on Approval of Lilly’s Obesity Pill

Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly’s once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." (Source: Bloomberg)

Open